This Viewpoint discusses supply and demand for glucagon-like peptide 1 (GLP-1) receptor agonists and concerns with using compounded drugs to fill this demand.
No takes yet. Share an insight, caveat, or question.
Mattingly et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: